Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines (NASDAQ:RVMD) has begun treating patients in RASolute 303, a global Phase 3 trial of daraxonrasib for previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
The randomized, open-label study compares daraxonrasib as monotherapy and combined with gemcitabine plus nab-paclitaxel versus standard-of-care gemcitabine and nab-paclitaxel, enrolling patients irrespective of tumor RAS genotype. Primary endpoints are progression-free survival and overall survival. Daraxonrasib is being evaluated in four global Phase 3 registrational trials, including three in PDAC and one in NSCLC.
Revolution Medicines (Nasdaq:RVMD) will present nine oral and poster presentations at the AACR Annual Meeting, April 17–22, 2026 in San Diego. Highlights include Phase 1 zoldonrasib (G12D) data in KRAS G12D NSCLC (plenary) and Phase 1/2 daraxonrasib datasets in first-line metastatic PDAC (mini-symposium).
Presentations also cover a new class of catalytic RAS(ON) inhibitors addressing emergent resistance and multiple preclinical and clinical RAS(ON) research topics.
Revolution Medicines (Nasdaq: RVMD) reported Q4 and full-year 2025 results and clinical progress on Feb 25, 2026. The company holds $2.0 billion in cash and received a $250 million royalty tranche, with $1.75 billion more committed. R&D and G&A rose materially; net loss was $364.9M in Q4 and $1.1B for 2025. Full-year 2026 GAAP operating expense guidance is $1.6–1.7B.
Clinical highlights: RASolute 302 pivotal readout expected in H1 2026; five ongoing Phase 3 trials and three planned; initiated RASolute 305 and advanced RMC-5127 into first-in-human dosing. Zoldonrasib received FDA Breakthrough Therapy designation for G12D NSCLC.
Revolution Medicines (Nasdaq: RVMD) said CEO Mark A. Goldsmith, M.D., Ph.D., will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.
According to the company, a live webcast will be available and a replay will remain on the company website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026 after market close. A senior management webcast will begin at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and corporate progress. A replay will be available on the company website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) announced that Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.
According to the company, the session will be webcast live and a replay will be available on the company's investor website for at least 14 days following the event.
Revolution Medicines (NASDAQ:RVMD) announced dosing of the first patient in the first-in-human trial RMC-5127-001 (NCT07349537), evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor.
The open-label trial will assess safety, tolerability, pharmacokinetics and preliminary antitumor activity as monotherapy and in combination in patients with RAS G12V–mutated PDAC, CRC and NSCLC. RMC-5127 is the company’s fifth disclosed mutant-selective RAS(ON) inhibitor and fourth clinical-stage program, targeting an estimated ~48,000 U.S. patients diagnosed annually with RAS G12V–driven cancers.
Revolution Medicines (Nasdaq: RVMD) announced that the U.S. FDA granted Breakthrough Therapy Designation to zoldonrasib for adults with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 therapy and platinum chemotherapy. The designation is based on data from the monotherapy cohort of the Phase 1 RMC-9805-001 trial, which demonstrated encouraging antitumor activity and acceptable safety and tolerability. Zoldonrasib is a tri-complex RAS(ON) G12D-selective covalent inhibitor that binds cyclophilin A. This is the first Breakthrough Therapy Designation for an investigational drug specifically targeting RAS G12D in NSCLC and follows prior designations for the company's daraxonrasib and elironrasib.
Revolution Medicines (Nasdaq: RVMD) said CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT.
The presentation will be available via live webcast at the company's investor events page and a replay will be posted on the website for at least 14 days after the live presentation.
Revolution Medicines (NASDAQ:RVMD) announced on Dec 18, 2025 that the first patient was randomized in RASolute 304, a global, open-label Phase 3 trial of daraxonrasib in resectable pancreatic ductal adenocarcinoma (PDAC) after surgery and perioperative chemotherapy.
RASolute 304 plans to enroll approximately 500 patients with oncogenic RAS mutations and will evaluate whether daraxonrasib improves disease-free survival versus observation; secondary endpoints include overall survival, safety, and tolerability. Daraxonrasib is being evaluated in four global Phase 3 trials, including three in PDAC and one in RAS mutant non-small cell lung cancer.